Skip to main content
Retour
Watch Compare

Ernexa Therapeutics Inc.

Qualité des données : 100%
Également cotée sous ERNAW Nasdaq
ERNA
Nasdaq Manufacturing Chemicals
0,21 €
▼ 0,01 € (-6,36%)
Cap. Boursière: 6,05 M
Prix
0,21 €
Cap. Boursière
6,05 M
Fourchette du Jour
0,21 € — 0,22 €
Fourchette 52 Semaines
0,18 € — 4,05 €
Volume
214 540
Ouverture 0,21 €
Moyenne 50J / 200J
0,44 €
53,54% below
Moyenne 50J / 200J
1,23 €
83,20% below

Quick Summary

Points Clés

Negative free cash flow of -7,05 M
Capital efficient — spends only 6,36% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-351,48%
En dessous de la moyenne du secteur (-53,41%)
ROIC-164,31%
Net Margin-2419,93%
Op. Margin-1601,20%

Sécurité

Debt / Equity
N/A
Current Ratio1,58
Interest Coverage-423,59

Valorisation

PE (TTM)
-0,43
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,70
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,4 -1,5
P/B 1,7 1,6
ROE % -351,5 -53,4
Net Margin % -2419,9 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 192,55%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 582 000,0 Net Income (TTM) -14,08 M
ROE -351,48% ROA -204,77%
Gross Margin 83,51% Operating Margin -1601,20%
Net Margin -2419,93% Free Cash Flow (TTM) -7,05 M
ROIC -164,31% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,58
Interest Coverage -423,59 Asset Turnover 0,08
Working Capital 1,24 M Tangible Book Value 1,53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,43 Forward P/E N/A
P/B Ratio 1,70 P/S Ratio 10,40
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -116,55%
Market Cap 6,05 M Enterprise Value 6,05 M
Per Share
EPS (Diluted TTM) -2,24 Revenue / Share 0,02
FCF / Share -0,24 OCF / Share -0,24
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 6,36% FCF Conversion 50,09%
SBC-Adj. FCF -8,62 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 582 000,0 582 000,0 68 000,0 — —
Net Income -14,08 M -44,54 M -21,67 M -24,58 M -122,31 M
EPS (Diluted) -2,24 -3,26 -4,08 -8,06 -2,82
Gross Profit 486 000,0 486 000,0 -168 000,0 — —
Operating Income -9,32 M -15,67 M -21,14 M -33,22 M -113,55 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A 65 000,0 139 000,0 84 000,0 161 000,0 117 000,0
Interest Expense 22 000,0 174 000,0 614 000,0 — —
Income Tax -45 000,0 30 000,0 -3 000,0 45 000,0 5 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5,83 M 5,27 M 49,13 M 22,28 M 32,43 M
Total Liabilities 3,43 M 3,57 M 46,90 M 10,17 M 25,93 M
Shareholders' Equity 2,40 M 1,70 M 2,23 M 12,11 M 6,50 M
Total Debt — — — — —
Cash & Equivalents — 1,73 M 7,58 M 11,45 M —
Current Assets 3,13 M 2,35 M 9,60 M 13,68 M 18,77 M
Current Liabilities 3,11 M 2,94 M 6,57 M 7,65 M 3,68 M